Organon & Co | OGN - Current Assets


Organon & Co reported $4.93B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Celltrion KRW 481.57B 10.97B Mar/2026
Cspc Pharmaceutical CNY 22.25B 359.48M Dec/2025
Deva Holding AS TRY 9.13B 1.61B Sep/2023
Dianthus Therapeutics USD 1.12B 710.47M Mar/2026
Divis Laboratories Ltd INR 110.96B 12.53B Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Kangmei Pharma CNY 6.8B 225.83M Mar/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Laboratorios Farma EUR 509.33M 128.63M Dec/2023
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.75M 1.79M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Neuren Pharmaceuticals AUD 332.23M 11.98M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Organigram Holdings CAD 250.09M 6.46M Mar/2026
Organon & Co USD 4.93B 580M Mar/2026
Ovoca Bio EUR 2.07M 510K Dec/2025
Pharma Mar EUR 280.95M 7.5M Jun/2026
Qiagen NV USD 1.54B 454.82M Mar/2026
Sartorius EUR 1.64B 280M Jun/2026
Sino Biopharmaceutical CNY 33.82B 9.13B Jun/2025
Tilray USD 729.32M 28.18M Sep/2025
Zealand Pharma A/S 15.02B 652.12M Mar/2026